AIM ImmunoTech (AIM) EBT Margin (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly EBT Margin came in at 14654.55% in Q1 2026, up 918920.0% YoY from N/an in Q1 2025, and up 4.84% on a QoQ basis from 15400.0% in Q4 2025.
AIM ImmunoTech (AIM) EBT Margin (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of EBT Margin data on file, last reported at 14654.55% in Q1 2026.
- Quarterly EBT Margin rose 918920.0% year-over-year to 14654.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14924.47% (down 64981.0% YoY) and the FY2025 annual result came in at 66495.45%, down 2964193.0% from the prior year.
- EBT Margin rose to 14654.55% in Q1 2026, from 15400.0% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 9173.47% in Q1 2023 to a low of 32171.43% in Q3 2022.
- A 5-year average of 16181.26% and a median of 14654.55% in 2026 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin plunged 1679567 bps — and 2023, when it jumped 1400404 bps.
- Tracing AIM's EBT Margin over 5 years: stood at 10058.93% in 2022, then slumped by 116 bps to 21755.38% in 2023, then surged by 39 bps to 13304.44% in 2024, then retreated by 16 bps to 15400.0% in 2025, then gained by 5 bps to 14654.55% in 2026.
- The last three EBT Margin figures came in at 14654.55% (Q1 2026), 15400.0% (Q4 2025), and 10134.62% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | -14,646.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -27,438.46% |
| Mar 31, 2026 | -14,654.55% |
| Dec 31, 2025 | -15,400.00% |
| Sep 30, 2025 | -10,134.62% |
| Jun 30, 2025 | -19,744.00% |
| Mar 31, 2025 | -23,843.75% |
| Dec 31, 2024 | -13,304.44% |
| Sep 30, 2024 | -13,451.43% |
| Jun 30, 2024 | -12,662.00% |
| Mar 31, 2024 | -20,767.50% |
| Dec 31, 2023 | -21,755.38% |
| Sep 30, 2023 | -18,167.39% |
| Jun 30, 2023 | -13,478.57% |
| Mar 31, 2023 | -9,173.47% |
| Dec 31, 2022 | -10,058.93% |
| Sep 30, 2022 | -32,171.43% |
| Jun 30, 2022 | -16,186.67% |
| Mar 31, 2022 | -10,127.27% |
| Dec 31, 2021 | -14,890.00% |
| Sep 30, 2021 | -15,375.76% |